218 related articles for article (PubMed ID: 29548318)
41. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
Sullivan SD; Turk F
Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
[TBL] [Abstract][Full Text] [Related]
42. Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: A population-based observational study.
Bloom CI; de Preux L; Sheikh A; Quint JK
PLoS Med; 2020 Jul; 17(7):e1003145. PubMed ID: 32692744
[TBL] [Abstract][Full Text] [Related]
43. Association between consistent omalizumab treatment and asthma control.
Lafeuille MH; Gravel J; Zhang J; Gorsh B; Figliomeni M; Lefebvre P
J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
[TBL] [Abstract][Full Text] [Related]
44. Comparison of allergic asthma patients treated with omalizumab and non-allergic patients treated with continuous oral corticosteroids: results of five year follow-up therapies.
Gemicioğlu B; Çalışkaner Öztürk B; Duman B
Tuberk Toraks; 2016 Jun; 64(2):97-104. PubMed ID: 27481075
[TBL] [Abstract][Full Text] [Related]
45. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
46. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
[TBL] [Abstract][Full Text] [Related]
47. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
Schreiber J; Schwab Sauerbeck I; Mailänder C
Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
[TBL] [Abstract][Full Text] [Related]
48. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.
Settipane RA; Kreindler JL; Chung Y; Tkacz J
Ann Allergy Asthma Immunol; 2019 Dec; 123(6):564-572.e3. PubMed ID: 31494235
[TBL] [Abstract][Full Text] [Related]
49. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
Zhou H; Lu Y; Wu B; Che D
J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
[No Abstract] [Full Text] [Related]
51. Impact of omalizumab on medical cost of childhood asthma in Japan.
Yoshikawa H; Iwata M; Matsuzaki H; Ono R; Murakami Y; Taba N; Honjo S; Motomura C; Odajima H
Pediatr Int; 2016 May; 58(5):425-8. PubMed ID: 27173421
[TBL] [Abstract][Full Text] [Related]
52. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.
Colombo GL; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Bruno GM; Pitotti C; Menzella F
Ther Adv Respir Dis; 2019; 13():1753466619841350. PubMed ID: 31035904
[TBL] [Abstract][Full Text] [Related]
53. Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma.
Buendia JA; Guerrero Patiño D; Cossio-Giraldo YE
J Asthma; 2022 Oct; 59(10):2016-2023. PubMed ID: 34551659
[TBL] [Abstract][Full Text] [Related]
54. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
[TBL] [Abstract][Full Text] [Related]
55. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE
J Manag Care Pharm; 2006 May; 12(4):310-21. PubMed ID: 16792437
[TBL] [Abstract][Full Text] [Related]
56. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
[TBL] [Abstract][Full Text] [Related]
57. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
[TBL] [Abstract][Full Text] [Related]
58. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
59. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
60. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
